ADDORA
Study details
Study purpose: Evaluation or phase- out obv Adalimumab concentrations vs. disease activity for a moment is (cost)effective
Symptoms/Diagnose: RA
Disease phase: Active RA
Indication/Medication: Start Adalimumab if 1e biological, either <16 weeks of Adalimumab treatment
In short
Key points
RA and pre-RADiseases
Rheumatoid arthritisCommitted staff members
Contact us
addora@reade.nlMore studies
3TR - Flare study
Research on biomarkers for developing a flare in SLE
- SLE
- Systemic Lupus Erythematosus
- Broens, B. (Bo)
IgG4 in vasculitis
IgG4/IgG RNA ratio as a disease activity marker in vasculitis
- General
- Vasculitis
- Weele, L. van der (Linda)
FaMaLE
Study of failing immune tolerance between mother and fetus as cause of pregnancy complications in SLE
- SLE
- Systemic Lupus Erythematosus
- Dankers, W. (Wendy)
JAKARTA
Evaluation effect of Filgotinib on heart through cardiac MRI/CT in RA
- RA and pre-RA
- Rheumatoid arthritis
- Bas Dijkshoorn
Onderzoek not found.
PsA BIOnd
Observational cohort study of Guselkumab (Tremfya) and anti- IL17 therapy in PSA
- SpA and pre-SpA
- Spondylarthritis
- Groothuizen, S. (Sam)
PO Box 7057
1007 MB Amsterdam
The Netherlands